Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux®1-E Foam, 0.05%, of Mylan Pharmaceuticals Inc.
According to IQVIA™ sales data forthe 12 month period ending July 2019, the Olux®-E Foam, 0.05% market2 achieved annual sales of approximately $11.1 million*.
Glenmark's current portfolio consists of 161 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.383.1 as compared to the previous close of Rs. 391.25. The total number of shares traded during the day was 19411 in over 667 trades.
The stock hit an intraday high of Rs. 392.55 and intraday low of 381.65. The net turnover during the day was Rs. 7494533.
1 All brand names and trademarks are the property of their respective owners.
2 Market includes brand and all available therapeutic equivalents
*IQVIA™ National Sales Perspectives: Retail & Non-Retail, July 2019